ALT - Altimmune Inc logo

Altimmune Inc

ALT

Altimmune Inc develops peptide-based therapeutics targeting serious liver diseases and obesity. Its lead candidate, pemvidutide, is in Phase 3 trials for metabolic dysfunction-associated steatohepatitis and alcohol-related liver diseases.

βš•οΈ Healthcare NASDAQ Listed 2005 $ USD
$1,000 invested 5 years ago β†’$233today

Score Overview

1 Year
Score
Net Growth-4.16%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth-24.39%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score3.4
Net Growth5.49%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth-99.30%
Rev Trend40%
Revenue Consistencyβ€”
10 Years
Score
Net Growth-147.33%
Net Trend40%
Net Income Consistency
Rev Growth-99.41%
Rev Trend38%
Revenue Consistency
20 Years
Score2.3
Net Growth-90x
Net Trend45%
Net Income Consistency
Rev Growth-98.32%
Rev Trend44%
Revenue Consistency
All Time
Score
Net Growth-330x
Net Trend48%
Net Income Consistency
Rev Growth-94.71%
Rev Trend47%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Altimmune Inc has ranked, year by year

Measure
Fundamentals Window

Showing 1 year ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • ALT

2011: 94.5% Β· 2021: 56.7% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 2.97β€”
1 Year2025-09-29
$ 3.79-21.64%
5 Years2021-09-29
$ 12.76-76.72%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 31K-$ 91M$ 326M
2025$ 41K-$ 88M$ 273M
2024$ 20K-$ 95M$ 131M
2023$ 426K-$ 88M$ 197M
2022-$ 68K-$ 84M$ 184M
2021$ 4M-$ 97M$ 190M
2020$ 8M-$ 49M$ 215M
2019$ 5M-$ 20M$ 37M
2018$ 10M-$ 39M$ 33M
2017-$ 46M$ 8M
2016$ 5M$ 193M$ 220M
2015$ 10M-$ 3M$ 15M
2014$ 10M-$ 9M$ 18M
2013$ 17M-$ 11M$ 10M
2012$ 25M-$ 4M$ 12M
2011$ 24M-$ 3M$ 11M
2010$ 20M-$ 34M$ 11M
2009$ 27M-$ 32M$ 5M
2008$ 32M-$ 36M$ 22M
2007$ 14M-$ 13M$ 52M
2006$ 1M$ 1M$ 675.3K
IPO2005$ 586.07K$ 277.3K$ 1M
ALT - Altimmune Inc logo

Altimmune Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 8M to $ 41K and net income went from -$ 49M to -$ 88M. Revenue increased in 2 of those 5 years; net income in 2.

Between 2015 and 2025, revenue declined from $ 10M to $ 41K and net income went from -$ 3M to -$ 88M. Revenue increased in 4 of those 10 years; net income in 4.

Altimmune Inc currently holds a 20-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.

Membership

Continue ALT’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies